Oralis

At Oralis, our mission is to revolutionize global immunization through a needle-free, oral mucosal norovirus vaccine. By targeting primary mucosal entry points, we provide superior protection while eliminating the logistical barriers of traditional cold-chain distribution. Its stability at room temperature and easy delivery via a press-on strip or retainer-based gel allow it to be easily deployed around the world. Furthermore, the synthetic-biology-based modular framework of our vaccine allows for adaptation of our platform to combat emerging global health threats beyond norovirus. We are committed to democratizing healthcare, delivering rapid, painless, and scalable solutions that protect even the most remote populations.

While modern vaccines can be highly effective, their real-world impact is constrained by infrastructure, administration requirements, and limited targeting towards specific viral pathways. A central limitation lies in cold-chain dependence. Most vaccines must be stored and transported within narrow temperature ranges, introducing cost, fragility, and inequity into distribution systems. Cold-chain logistics account for a significant portion of total vaccine delivery costs and are highly vulnerable to disruption. In many low- and middle-income settings, unreliable electricity and limited refrigeration infrastructure result in high rates of vaccine waste and restricted access. As a result, the populations most in need of protection are often the least able to receive it. At the same time, current vaccine delivery methods rely heavily on intramuscular injections, which require trained healthcare personnel and clinical infrastructure. This creates bottlenecks in large-scale immunization efforts and limits reach in regions where healthcare workers are scarce. The use of needles also reduces patient compliance and completion of vaccination schedules, particularly in pediatric populations. There is an opportunity to increase vaccine design to more effectively target specific viral pathways. Many pathogens, including norovirus, enter through mucosal surfaces such as the oral and gastrointestinal tract, yet most vaccines are optimized to generate systemic immunity rather than localized protection at the site of entry. This reduces their effectiveness in preventing infection and transmission, particularly for highly contagious diseases. Norovirus itself affects hundreds of millions of people each year and leads to significant mortality, yet there is still no approved vaccine. The burden is particularly high in low-resource settings, where the same distribution and infrastructure barriers further limit access to potential solutions. In addition, vaccine development remains largely disease-specific rather than platform-based. Each new disease often requires building a new delivery system alongside the antigen itself, slowing development timelines and limiting scalability. In the context of emerging infectious diseases, this lack of modularity makes it difficult to respond quickly and efficiently to new threats. Oralis was created to alleviate such structural limitations. By combining room-temperature stability, oral delivery, mucosal targeting, and a modular synthetic biology platform, Oralis redefines vaccination as a system-level solution rather than a single product. It eliminates dependence on cold-chain infrastructure, reduces the need for trained clinical administration, and aligns immune protection with how infections actually occur. Beyond norovirus, Oralis is furthermore designed as a scalable platform that can be adapted to multiple pathogens, enabling faster development and a broader impact. In doing so, it addresses the logistical, economic, and behavioral barriers that prevent vaccines from reaching their full potential. Oralis is therefore necessary not simply to introduce a new vaccine, but to overcome the constraints that limit global immunization today.